Visit
The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…
A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an…
VJOncology are excited to highlight the latest in immuno-oncology from the 37th Annual Meeting of the Society for Immunotherapy in…
Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…
Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…
Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…
EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…
VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!
In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to…
VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!
Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!
VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium!
The San Antonio Breast Cancer Symposium (SABCS) took place on the 7-10 December 2021, both virtually and in-person. We heard…
The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting…
Check out our top picks from ESMO 2021!
Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates
Keep up to date with all the latest news with our monthly newsletter